Adam Sowalsky
@adam-sowalsky.bsky.social
Translational scientist at NCI/NIH. Giving prostate cancer the finger.
I'm pleased to share the latest paper from my lab, published online today at @jclinical-invest.bsky.social www.jci.org/articles/vie.... Patients with high risk prostate cancers that resist intense androgen derivation therapy harbor cancer cells that are sensitive to HER2 inhibitors. A "skytorial."
JCI -
Localized high-risk prostate cancer harbors an androgen receptor activity-low subpopulation susceptible to HER2 inhibition
www.jci.org
September 4, 2025 at 4:46 PM
I'm pleased to share the latest paper from my lab, published online today at @jclinical-invest.bsky.social www.jci.org/articles/vie.... Patients with high risk prostate cancers that resist intense androgen derivation therapy harbor cancer cells that are sensitive to HER2 inhibitors. A "skytorial."
Reposted by Adam Sowalsky
🚨New publication alert🚨
Typeset version of our most recent publication in European Urology just hit!
Wonderful collaboration with @mishabeltran.bsky.social @adam-sowalsky.bsky.social and Pete Nelson at @fredhutch.bsky.social!
👇
Typeset version of our most recent publication in European Urology just hit!
Wonderful collaboration with @mishabeltran.bsky.social @adam-sowalsky.bsky.social and Pete Nelson at @fredhutch.bsky.social!
👇
May 21, 2025 at 12:56 PM
🚨New publication alert🚨
Typeset version of our most recent publication in European Urology just hit!
Wonderful collaboration with @mishabeltran.bsky.social @adam-sowalsky.bsky.social and Pete Nelson at @fredhutch.bsky.social!
👇
Typeset version of our most recent publication in European Urology just hit!
Wonderful collaboration with @mishabeltran.bsky.social @adam-sowalsky.bsky.social and Pete Nelson at @fredhutch.bsky.social!
👇
When I was on paternity leave with my son (who is now 6-1/2) my good friend and long-time collaborator Huihui Ye called and asked me to help with genomic profiling of a rare variant of kidney cancer. That paper was published today in @modernpathology.bsky.social. authors.elsevier.com/c/1l3Ih3B8d9...
May 8, 2025 at 1:42 PM
When I was on paternity leave with my son (who is now 6-1/2) my good friend and long-time collaborator Huihui Ye called and asked me to help with genomic profiling of a rare variant of kidney cancer. That paper was published today in @modernpathology.bsky.social. authors.elsevier.com/c/1l3Ih3B8d9...
Reposted by Adam Sowalsky
Great mid-week news on the publication front!
Could it be that our GPC3-selective radiotheranostics agents aimed at #HCC could be repurposed for neuroendocrine prostate cancer?
Fun collaboration with Dr. Adam Sowalsky, Himisha Beltran and Peter Nelson!
Stay tuned!
#radiopharmaceuticals #pcsm
Could it be that our GPC3-selective radiotheranostics agents aimed at #HCC could be repurposed for neuroendocrine prostate cancer?
Fun collaboration with Dr. Adam Sowalsky, Himisha Beltran and Peter Nelson!
Stay tuned!
#radiopharmaceuticals #pcsm
May 7, 2025 at 7:39 PM
Great mid-week news on the publication front!
Could it be that our GPC3-selective radiotheranostics agents aimed at #HCC could be repurposed for neuroendocrine prostate cancer?
Fun collaboration with Dr. Adam Sowalsky, Himisha Beltran and Peter Nelson!
Stay tuned!
#radiopharmaceuticals #pcsm
Could it be that our GPC3-selective radiotheranostics agents aimed at #HCC could be repurposed for neuroendocrine prostate cancer?
Fun collaboration with Dr. Adam Sowalsky, Himisha Beltran and Peter Nelson!
Stay tuned!
#radiopharmaceuticals #pcsm
Reposted by Adam Sowalsky
Happy to finally have this work out. Enza-resistance in PCa via upregulation of ARv7 and increased chromatin accessibility.
Congrats to lead author (and newly minted PCF YI) Larysa Poluben! She put a tremendous amount of work into this and deserves all the 👏👏👏.
pubmed.ncbi.nlm.nih.gov/39709604/
Congrats to lead author (and newly minted PCF YI) Larysa Poluben! She put a tremendous amount of work into this and deserves all the 👏👏👏.
pubmed.ncbi.nlm.nih.gov/39709604/
Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer - PubMed
Androgen receptor (AR) splice variants, of which ARv7 is the most common, are increased in castration-resistant prostate cancer, but the extent to which they drive AR activity is unclear. We generated...
pubmed.ncbi.nlm.nih.gov
January 19, 2025 at 1:56 PM
Happy to finally have this work out. Enza-resistance in PCa via upregulation of ARv7 and increased chromatin accessibility.
Congrats to lead author (and newly minted PCF YI) Larysa Poluben! She put a tremendous amount of work into this and deserves all the 👏👏👏.
pubmed.ncbi.nlm.nih.gov/39709604/
Congrats to lead author (and newly minted PCF YI) Larysa Poluben! She put a tremendous amount of work into this and deserves all the 👏👏👏.
pubmed.ncbi.nlm.nih.gov/39709604/